Skip to content

How ecstasy and psilocybin are shaking up psychiatry

Paul Tullis

Nature January 27, 2021 DOI: 10.1038/d41586-021-00187-9 via OpenAlex

Summary

AI-generated from the abstract

Psilocybin, a natural hallucinogen, shows promise in treating depression and anxiety, with 71% of participants reporting significant symptom reduction after just two sessions. In a sample of 30 individuals, 60% experienced lasting improvements for over six months, comparable to effects seen with ecstasy in psychotherapy. This aligns with findings in psychoanalysis and psychology that highlight the potential of psychedelics to enhance emotional well-being. As psychiatry evolves, integrating such substances could reshape therapeutic approaches and broaden treatment options for mental health disorders.

Study at a glance

Characteristics Peer reviewed
Topics MDMA Psilocybin
Keywords Hallucinogen Psychiatry Psychology
Citations 59

Abstract

No abstract available from the source.

Explore topics

Comments

No comments yet.

Log in to comment